Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.57 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.57 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6828319 | 0.98 | HDAC1 (0.61) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL31268672 | 0.82 | HDAC1 (0.62) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL2732281 | 0.82 | HDAC1 (0.62) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL22711347 | 0.79 | HDAC1 (0.69) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL1234255 | 0.79 | HDAC1 (0.59) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL20906843 | 0.79 | HDAC1 (0.59) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL5361880 | 0.79 | HDAC1 (0.74) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL2000041 | 0.79 | HDAC1 (0.74) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL1116605 | 0.78 | THRB (0.66) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL20916923 | 0.78 | HDAC1 (0.57) | HDAC1HDAC6THRBLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | HK INNO.N CORPORATION (KR) | 2024-12-31 | — | — | US | claimed |
| US-11655268-B2 | Nucleoside or nucleotide derivatives, and uses thereof | ST PHARM CO., LTD. (KR) | 2023-05-23 | — | — | US | claimed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | claimed |
| EP-4135519-A1 | ACTIVE COMPOUND COMBINATIONS AND FUNGICIDE COMPOSITIONS COMPRISING THOSE | Bayer Aktiengesellschaft (DE) | 2023-02-22 | — | — | EP | claimed |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HK INNO.N CORPORATION (KR) | 2022-01-13 | — | — | US | claimed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | claimed |
| WO-2021209368-A1 | ACTIVE COMPOUND COMBINATIONS AND FUNGICIDE COMPOSITIONS COMPRISING THOSE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-21 | — | — | WO | claimed |
| EP-3873893-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | claimed |
| US-20210040135-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | ST PHARM CO., LTD. (KR) | 2021-02-11 | — | — | US | claimed |
| EP-3744726-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | ST Pharm Co., Ltd. (KR) | 2020-12-02 | — | — | EP | claimed |
| EP-2419420-A1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | Glaxo Group Limited (GB) | 2012-02-22 | — | — | EP | claimed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2010119078-A1 | INDOLE DERIVATIVE MODULATORS OF THE ALPHA 7 NACHR | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | claimed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | claimed |
| WO-2008130323-A1 | NOVEL 8-PIPERAZINE-TETRAHYDRONAPHTALENE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1893566-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LTD. (GB) | 2008-03-05 | — | — | EP | claimed |
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | claimed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| WO-2006131711-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040135-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | PNP, SLC28A1, NT5C3B | HDAC1 3018/4885HDAC6 2244/4885THRB 4152/4885 |
| US-11655268-B2 | Nucleoside or nucleotide derivatives, and uses thereof | PNP, SLC28A1, NT5C3B | HDAC1 2854/4885HDAC6 2440/4885THRB 4171/4885 |
| US-12180185-B2 | Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | MAP3K20, MAP3K1, MAP3K15 | HDAC1 1035/4885HDAC6 753/4885THRB 1417/4885 |
| US-20220009902-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | MAP3K20, MAP3K1, MAP3K15 | HDAC1 907/4885HDAC6 703/4885THRB 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.